Cell and Gene Therapy Manufacturing in Canada: GMP Obligations Under Health Canada's Advanced Therapeutic Products Framework

Sponsors developing cell and gene therapies in Canada consistently underestimate one thing: how different the GMP requirements are from conventional pharmaceutical manufacturing. The equipment is different. The starting materials are different. The batch sizes — sometimes a single patient dose — are fundamentally different. And Health Canada’s expectations for controlling all of it are, in many ways, more demanding than anything most teams encountered when they built their small-molecule or even conventional biologics programs.

This isn’t a post about the clinical or scientific side of cell and gene therapy (CGT) development. It’s about what Canada GMP actually looks like in a facility producing these products, what Health Canada inspectors focus on when they walk through your door, and where established pharmaceutical manufacturers tend to trip up when they move into this space for the first time.

What Health Canada Classifies as an Advanced Therapy Product

Canada doesn’t use the term “advanced therapy medicinal product” (ATMP) in its regulatory framework — that language belongs to the EU’s ATMP Regulation (EC 1394/2007). But the underlying product categories are essentially parallel: somatic cell therapies, gene therapies (including gene-edited cell products), and tissue-engineered products.

In Canada, these products are regulated as biologics under Schedule D of the Food and Drug Regulations, with scientific oversight sitting within Health Canada’s Biologics and Genetic Therapies Directorate (BGTD). That classification has immediate practical consequences. The regulatory machinery governing these products — submission pathways, GMP expectations, and post-market obligations — draws from the biologics framework, not the conventional pharmaceutical framework. Those are not the same thing, and treating them as interchangeable is one of the more costly assumptions a sponsor can make early in development.

For manufacturers, this means your Drug Establishment Licence (DEL) must explicitly list Schedule D biologic manufacturing activities. A DEL that covers conventional drug manufacturing does not authorize you to produce gene therapies or viral vectors. If your program involves manufacturing a lentivirus, AAV, or other viral vector as a product component, that activity requires separate authorization under your DEL — and the GMP expectations attached to that authorization are considerably more demanding than most manufacturers initially expect.

Canada GMP Requirements That Specifically Challenge CGT Facilities

Health Canada’s GMP guidance for biologics — primarily GUI-0027 for drug products and GUI-0028 for active pharmaceutical ingredients, supplemented by the ICH Q5 series (Q5A through Q5E) — forms the backbone of what inspectors apply during CGT facility assessments. The challenge is that applying these guidelines to a cell or gene therapy program raises problems that simply don’t arise in conventional pharmaceutical manufacturing.

Lot size and lot release. A conventional manufacturer can batch test 10,000 tablets, release on statistical sampling, and retain representative reserve samples. An autologous cell therapy — manufactured from a specific patient’s own cells — might consist of a single infusion bag. Lot release for that product needs a prospectively validated testing strategy that generates meaningful quality data despite the complete absence of statistical power. Health Canada expects to see a scientifically justified release testing program, not one copied wholesale from a conventional biologics approach.

In-process controls and parametric release. Some CAR-T cell therapies have shelf lives measured in hours — typically 72 hours or less from final manufacturing to patient administration. There isn’t time to wait for all end-product testing to complete before release decisions must be made. Health Canada inspectors increasingly scrutinize whether manufacturers have robust parametric release programs, where well-characterized in-process controls substitute for end-product testing within pre-defined acceptance criteria. These programs require validation, documented rationale, and linkage to your overall process characterization data.

Viral safety. If your manufacturing process uses viral vectors, the viral safety requirements are genuinely demanding and non-negotiable. ICH Q5A (Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin) applies in full, and Health Canada expects a comprehensive viral clearance strategy — not just the standard adventitious agent testing that suffices for many conventional biologics. This typically means orthogonal clearance steps (for example, affinity chromatography combined with low-pH inactivation and nanofiltration), independently validated clearance studies using scaled-down process models, and detailed documentation of the viral safety rationale in your drug submission.

Starting material controls. For autologous therapies, the starting material is the patient. For allogeneic therapies, donor screening and eligibility testing requirements apply. Health Canada’s expectations for donor eligibility testing broadly align with international standards, but inspectors have cited manufacturers for inadequate documentation of donor screening records, failure to establish and justify acceptance criteria for cell banks derived from human donors, and gaps in the traceability chain linking the donor to the manufactured product lot.

The Drug Establishment Licence for CGT Facilities: Where Inspections Focus

Getting a DEL that covers Schedule D biologic manufacturing is not a paperwork exercise. Health Canada conducts a pre-licensing inspection of your facility before the DEL is issued for biologic activities, and that inspection covers considerably more than the physical plant.

Contamination control. CGT facilities often produce multiple products — sometimes at different clinical stages, sometimes using different viral vector systems — in the same physical space. Cross-contamination control, particularly between viral vectors, requires a documented, risk-based contamination control strategy that goes well beyond standard pharmaceutical facility design. Campaign manufacturing, physical segregation, equipment dedication policies, and HVAC design all need to be justified in the context of your specific product mix.

Environmental monitoring. Cleanroom classification for CGT manufacturing follows EU Annex 1 guidance (which Health Canada references for sterile product manufacturing), with Grade A / ISO 5 conditions required for all open manipulations involving living cells or viral vectors. The environmental monitoring program must address risks specific to your process — including the particular challenges of working with viable biological systems that can grow, adapt, and contaminate in ways that small-molecule products cannot.

Quality system maturity. For organizations entering CGT manufacturing from an academic or hospital-based cell therapy background, this is consistently where the largest compliance gaps appear. Health Canada expects a pharmaceutical-grade quality system in the spirit of ICH Q10 — functional change control, deviation management linked to impact assessment, a CAPA program that demonstrably closes root causes, and annual product reviews. An institutional cell therapy facility accustomed to producing investigational products under a research ethics board framework is typically not operating at this level of quality system maturity on first DEL application.

Traceability. For both autologous and allogeneic products, Health Canada expects end-to-end traceability from the patient or donor through every manufacturing step to administration. Your batch record and documentation system must link the final product to its specific biological starting material, unambiguously and without gaps. This is a higher traceability standard than most pharmaceutical batch record systems were originally designed to meet.

Regulatory Submission Pathways: CTAs and NDSs for CGT Products

Most Canadian CGT programs begin with a Clinical Trial Application (CTA). Health Canada’s published target for standard CTA review is 30 calendar days for most submissions. But complex gene therapy CTAs — particularly those involving novel vectors, first-in-human proposals, or manufacturing processes with limited prior regulatory precedent — frequently involve additional scientific exchanges that extend the practical timeline to somewhere in the range of 60 to 90 days before authorization is granted.

For market authorization, sponsors file a New Drug Submission (NDS). Health Canada’s standard NDS review target is 300 days. For products addressing serious or life-threatening conditions with no adequate alternative treatment — which describes most current gene therapy indications — sponsors can request priority review, reducing the target to 180 days. Priority review eligibility must be formally requested and granted by Health Canada before the submission is filed, not after.

The Notice of Compliance with Conditions (NOC/c) pathway is also relevant for CGT products where confirmatory randomized controlled trial evidence is difficult to generate in small patient populations. Health Canada can grant conditional approval based on promising early evidence, with binding post-market conditions requiring confirmatory data within defined timelines. But this pathway carries significant post-market regulatory obligations that need to be planned for during development, not addressed reactively after authorization.

Selecting a Canadian CMO or CRO for CGT Manufacturing

Unless you’re a large pharmaceutical company with an established biologics manufacturing footprint in Canada, a contract manufacturing or contract research organization is going to be part of your strategy. The landscape of Canadian CGT-capable CMOs is growing, but it’s still limited — and the technical requirements for cell therapy manufacturing in particular mean that not every DEL-holding pharmaceutical CMO is equipped to produce these products.

When evaluating a potential Canadian CMO for CGT work, there are a few things worth verifying before you get into capabilities presentations:

• Does their DEL explicitly list Schedule D biologics manufacturing, and does it cover your specific product modality?
• Can they demonstrate documented experience with autologous versus allogeneic versus viral vector manufacturing — not just theoretical capability?
• Does their cleanroom infrastructure meet the classification requirements for your product’s open-handling steps?
• Is their quality system genuinely at pharmaceutical GMP maturity, or is it built on research-lab quality culture with GMP language layered over the top?
• Do they have validated closed-system manufacturing capability for steps where cell or vector containment is required?

The GMP audit of a potential CGT CMO is more demanding than a standard pharmaceutical CMO audit. We recommend using an audit protocol that specifically addresses CGT manufacturing risks — contamination control strategy, starting material acceptance criteria, release testing approach, and chain-of-custody documentation — rather than adapting a generic pharmaceutical quality audit template for the purpose. The gaps that create inspection risk in a CGT facility are often invisible to an auditor who is primarily trained in conventional pharmaceutical manufacturing.

The Practical Takeaway

Cell and gene therapy manufacturing in Canada is not conventional pharmaceutical manufacturing adapted for biological starting materials. It’s a different discipline, operating under a different regulatory framework, with manufacturing challenges that require fundamentally different quality and GMP strategies. Health Canada’s expectations reflect that — even when the guidance documents don’t always articulate the distinctions as explicitly as manufacturers would find helpful.

If your team is planning a CGT program and approaching the manufacturing and regulatory strategy as a scaled version of a conventional biologics approach, you’re likely to encounter compliance gaps that delay your CTA authorization, your DEL, or both. Engaging with Canada GMP requirements specifically for advanced therapeutics from the earliest stages of your manufacturing process design — before you’ve committed to a facility configuration, a release strategy, or a starting material control approach — is the more defensible path. And the less expensive one.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Androxa. Learn more about our team

Talk to our team about Health Canada compliance. Contact us

Related from our network

• Analytical and Microbiological Testing for Biologic Manufacturers — Qalitex Laboratories provides ISO 17025-accredited testing services for pharmaceutical and biologic manufacturers requiring third-party lab support for Canadian regulatory submissions.
• EU ATMP Regulatory Requirements for Market Entry — Care Europe covers the EU’s Advanced Therapy Medicinal Products Regulation and what sponsors need to address when preparing for European market authorization alongside a Canadian program.